
A researcher at the center of questions about a biotech’s controversial experimental treatment for Alzheimer’s disease has lost five papers in PLOS One.
The journal says it is retracting the articles, by Hoau-Yan Wang and colleagues, over concerns about the integrity of the data and the images in the papers. Wang does not agree with any of the retractions.
As we’ve reported, Wang, of the CIty University of New York, helped conduct the studies that formed the backbone of the regulatory filing for the drug simufilam, which Cassava Sciences — formerly Pain Therapeutics — has been trying to bring to market. Cassava, according to a citizen’s petition to the FDA, has funded Wang’s lab for more than 15 years, and two of the now-retracted papers feature Lindsay Burns, a Cassava employee, as a co-author. (The citizen’s petition, which called on the FDA to halt Cassava’s trials, was filed by a law firm representing Cassava short sellers but eventually denied by the FDA because it was not an appropriate venue.)
Continue reading Five studies linked to Cassava Sciences retracted